The Broad Institute, Boston Children’s Hospital, and The Jackson Laboratory launched a Center for Therapeutic Genetics aimed at developing gene therapies for rare diseases while standardizing protocols to address regulatory and health-system friction. The center is working toward treating its first patient within three years. The initiative is supported by a $34.5 million ARPA-H grant awarded earlier this month to a Broad-led coalition, with early work centered on a gene-editing platform for rare pediatric epilepsies, including alternating hemiplegia of childhood (ATP1A3) and Dravet syndrome (SCN1A). The partners also plan to expand to additional indications such as liver disease. Program leaders positioned the strategy as shifting bespoke, patient-by-patient development toward repeatable therapeutic “procedures,” intended to improve access and reduce the need for separate regulatory pathways per use case.